Acceleron reported strong progress in its pipeline with key regulatory filings accepted and priority reviews granted for luspatercept, indicating potential near-term catalysts. The company's solid cash position and strategic growth initiatives further bolster investor confidence, despite reporting a net loss. Overall, these factors are likely to have a positive short-term impact on the stock.

[1]